Axsome Therapeutics Q2 Sales $87.166M Beat $86.659M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 sales of $87.166 million, surpassing the analyst estimate of $86.659 million by 0.58%. This marks an 86.65% increase from the same period last year.
August 05, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics reported Q2 sales of $87.166 million, beating the analyst estimate of $86.659 million by 0.58%. This represents an 86.65% increase from the same period last year, indicating strong growth.
The company's Q2 sales exceeded analyst expectations and showed significant year-over-year growth, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100